Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/30
$4.76+1.93 (+68.20%)
Close on Nov 18, 2026Market cap $34.58MP/E –Yield –
Cue Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cue Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$98.67M. For fiscal 2025 it was -$26.55M. The highest annual figure on record is -$23.23M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.55M | – |
| FY2024 | Dec 31, 2024 | -$41.50M | – |
| FY2023 | Dec 31, 2023 | -$52.15M | – |
| FY2022 | Dec 31, 2022 | -$53.23M | – |
| FY2021 | Dec 31, 2021 | -$43.71M | – |
| FY2020 | Dec 31, 2020 | -$45.04M | – |
| FY2019 | Dec 31, 2019 | -$36.77M | – |
| FY2018 | Dec 31, 2018 | -$38.70M | – |
| FY2017 | Dec 31, 2017 | -$23.23M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$87.70M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.35M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.30M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.82M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.42M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.38M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.24M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.30M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.97M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.13M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.02M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.09M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.23M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.43M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.97M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.76M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.52M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.44M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.03M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.41M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.35M | – |
See a number that looks wrong?